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ABSTRACT: In order to prevent hemorrhage during surgical procedures, a
wide range of hemostatic agents have been developed. However, their eﬃcacy
is variable; hemostatic devices that use bioactive components to accelerate
coagulation are dependent on natural sources, which limits reproducibility.
Hybrid devices in which chain-end reactive poly(ethylene glycol) is employed
as active component sometimes suﬀer from irregular cross-linking and
dissolution of the polar PEG when blood ﬂow is substantial. Herein, we
describe a synthetic, nonbioactive hemostatic product by coating N-
hydroxysuccinimide ester (NHS)-functional poly(2-oxazoline)s (POx-NHS)
onto gelatin patches, which acts by formation of covalent cross-links between
polymer, host blood proteins, gelatin and tissue to seal the wound site and
prevent hemorrhage during surgery. We studied diﬀerent process parameters
(including polymer, carrier, and coating technique) in direct comparison with
clinical products (Hemopatch and Tachosil) to obtain deeper understanding of
this class of hemostatic products. In this work, we successfully prove the hemostatic eﬃcacy of POx-NHS as polymer powders
and coated patches both in vitro and in vivo against Hemopatch and Tachosil, demonstrating that POx-NHS are excellent
candidate polymers for the development of next generation hemostatic patches.
1. INTRODUCTION
One of the main challenges during surgical procedures on
parenchymatous tissue is to attain control over bleeding.1
Suture control, electrocautery,2 and ultrasonic sealing3 often do
not suﬃce during operations on for example liver or kidneys.
As a result, procedures like hepatic resections4 or partial
nephrectomy5 require an alternative approach to control
bleeding. For this purpose, a wide range of topical hemostatic
products has been developed and are clinically available.6−8
The main class of hemostatic products is composed of
polymeric materials of biological origin such as starch,9
chitosan,10 oxidized regenerated cellulose,11,12 collagen, and
gelatin.13,14 These biocompatible and biodegradable products
accelerate the natural coagulation cascade and are available in
various forms (powder, sponges, dressings). Their hemostatic
action is generally limited, for example when large areas of
profuse bleedings should be treated. Moreover, animal-derived
products carry the risk of transmission of diseases via viral or
prion agents. Within this class, Tachosil (a collagen carrier
coated with human derived ﬁbrinogen and thrombin) is
considered a “gold standard” due to its widespread use in
liver resection.15 However, the high costs and the use of human
derived materials have stimulated the search for alternative
synthetic hemostatic products. As a result, synthetic polymer
sealants16 have been developed which act independently of the
natural coagulation cascade by their ability to seal oﬀ the
wound surface, thereby stopping the blood ﬂow. Although the
eﬃcacy of these products is reported to be superior over
naturally derived hemostats, the unknown biodegradation/
excretion proﬁle of some of these polymers as well as their
toxicity (e.g., for cyano-acrylates)17 are drawbacks of this class
of materials.
A more recent approach entails the development of hybrid
products, which combine the beneﬁcial properties of both
synthetic and natural polymers. Two examples are Veriset18 (an
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oxidized regenerated cellulose sheet impregnated with trilysine
and N-hydroxysuccinimide ester functional 4-arm poly-
(ethylene glycol) (PEG-4-arm NHS)) and Hemopatch19−21
(a porous collagen carrier coated with PEG-4-arm-NHS). Both
products have shown improved hemostatic eﬃcacy compared
to carriers without this coating21,22 and other commercially
available products.18,19 In case of Hemopatch, the mechanism
of action is based on instantaneous covalent cross-linking
between PEG-4-arm-NHS and amines present in tissues, blood
proteins and the collagen carrier, which seals oﬀ the wound site
and allows ﬁrm ﬁxation of the patch to the tissue. However, the
intrinsically fast cross-linking of PEG-4-arm-NHS might lead to
irregular sealing of the wound site (by inhomogeneous cross-
linking with tissue) or poor ﬁxation to tissue (by limited cross-
linking with the collagen carrier) rendering this hemostat less
eﬀective for some surgical bleedings. Moreover, the hydrophilic
nature of PEG can also cause the polymer to be ﬂushed away
from the carrier during hemorrhage, which leads to a poor
hemostatic action. These potential drawbacks might be solved
by modifying and ﬁne-tuning the polymer architecture and
properties. However, PEG has limited options for tailoring the
degree of functionalization (only via the end groups) and
polarity, which prompts further research on alternative
polymers with hemostatic activity.
Poly(2-oxazoline)s (or POx23−26) are promising polymers
for biomedical applications due to their versatile synthesis,27−29
favorable cytocompatibility,30−32 and promising excretabil-
ity.33−37 In terms of polymer architecture and function, POx
possesses important advantages over PEG-based systems when
applied in hemostatic materials. First, cationic ring opening
polymerization (CROP) allows for the introduction of both
functional side chains and end groups, which is not easily
achieved by anionic polymerization of PEG-based systems.
Moreover, this polymerization technique allows for the
synthesis of a range of copolymers, which makes it possible
to accurately control the polarity and degree of side-chain
functionalization of the resulting polymer.
In order to achieve optimal hemostatic performance, three
main aspects of the hemostatic device should be optimized,
namely, (1) the carrier, (2) the polymer coating, and (3) the
coating application method onto the carrier material. As a
carrier, we selected a porous gelatin sponge. Although this
carrier is animal derived, it has advantages over other carrier
materials, since it is fully biodegradable (4−8 weeks), shows
eﬀective uptake of blood and is already registered as a
hemostatic product.13 Moreover, primary amines are available
in gelatin to allow for the formation of covalent cross-links
between the carrier, blood proteins, and tissue in order to
create a gel that seals oﬀ the wound surface and stops the
bleeding (Figure 1).
Regarding polymer design, for optimal hemostatic perform-
ance, the polymer should have suﬃcient reactive moieties
(NHS-esters) for covalent cross-linking (e.g., with blood
proteins). The polymer composition should furthermore be
chosen in such a way that the polymers are soluble in water
(beneﬁcial for their biological activity) and in organic solvents
(beneﬁcial for polymer processing). Moreover, the reactive
moieties should be available for cross-linking, which requires
reactive side chains of suﬃcient ﬂexibility and length as well as
an overall polymer composition which is polar enough to allow
eﬀective wetting under physiological conditions. The cross-
linking capacity should be optimized to ensure that the polymer
has suﬃcient time to cross-link with the various components
(blood, carrier, and tissue).
Regarding the coating of the hemostatic patch, we
hypothesized that various parameters are important to achieve
the desired hemostatic properties. First, the reactive polymer
should be equally distributed over the carrier in order to obtain
homogeneous hemostatic properties over the whole area of the
coated patch. Second, the polymer and carrier should be
combined in such a way that undesired cross-linking during the
coating process is prevented. Moreover, after coating, porosity
should be partially conserved in order to obtain a hemostatic
patch with a dual mechanism of action of both gelatin (natural
Figure 1. Schematic overview of application method and mechanism of action of poly(2-oxazoline) coated hemostatic patches. (A) Preparation of
hemostatic patch by spray-coating POx-NHS onto a gelatin sponge. (B) Application of the patch onto the wound site. (C) Hemostasis is obtained by
covalent cross-linking between the gelatin sponge, POx-NHS, blood proteins, and tissue in order to create a gel which seals oﬀ the wound surface
and stops the bleeding.
Biomacromolecules Article
DOI: 10.1021/acs.biomac.7b00683
Biomacromolecules 2017, 18, 2529−2538
2530
coagulation cascade) and the reactive polymer (sealing oﬀ the
wound site by covalent cross-linking). Moreover, the blood
uptake of the coated patches should be satisfactory to allow for
cross-linking with all patch components (gelatin, reaction
polymer, blood, and tissue), but also resistant enough to
prevent excessive blood ﬂow through the patch.
In this work, we demonstrate a versatile strategy for the
preparation of a poly(2-oxazoline) based hemostatic device.
First, a series of NHS-ester functionalized POx (POx-NHS)
with diﬀerent ratios of NHS esters and polar groups was
synthesized. We studied the capacity for covalent cross-linking
between these polymers and whole blood (hemostatic
performance) in order to correlate the hemostatic performance
with the polarity of the polymers (measured by contact angle
measurements). With the preselected polymers, we utilized a
spraying procedure to create a series of homogeneously coated
patches. The coated patches were tested in vitro, for, for
example, blood uptake and cross-linking ability. The best-
performing patches in these tests were selected to demonstrate
in vivo eﬃcacy in a compromised liver and spleen injury model
of profuse bleedings in heparinized pigs.
2. MATERIALS AND METHODS
2.1. Materials. Gelatin sponges (Gelita Rapid, origin: porcine, 5 ×
8 × 0.2 cm) were obtained from Gelita Medical. Hemopatch was
obtained from Baxter (Deerﬁeld, IL, U.S.A.). Tachosil was obtained
f rom Takeda (L inz , Aus t r i a ) . Pentae ry th r i to l t e t r a -
(succinimidyloxysuccinyl) poly(ethylene oxide) (PEG-4-arm NHS)
was obtained from NOF America corporation. Heparinized human
whole blood was obtained from Sanquin (Nijmegen, The Nether-
lands).
2.2. Synthesis. Experimental procedures for the synthesis of P1−
P7 can be found in the Supporting Information.
2.3. Gelation Test. This experiment was performed using an
inverted vial test adapted from literature.38 Polymer powders (20 mg)
were mixed with freshly obtained heparinized human whole blood (1
mL) in a glass vial and vortexed until a visible gel was formed (gelation
time).
2.4. Contact Angle Measurements. Microscope coverslips (2
cm2) were soaked in absolute ethanol, sonicated (30 s) and dried
under reduced pressure for 15 min. Polymer ﬁlms were prepared by
spin-coating the polymer solutions (15 mg/mL in DCM, 1 mL) onto
the microscope coverslips (12000 rpm, 30 s) using a Spin 150 spin-
coater. Subsequently, the coated slides were dried overnight under
reduced pressure. Static contact angles were measured on an OCA-20
goniometer. For each measurement, 1 μL of doubly distilled water was
placed onto the spin-coated ﬁlms at room temperature. The spreading
of the droplet was imaged using a high speed video camera using 1
frame/second for 30 s. The contact angle was determined based upon
the Laplace Young ﬁtting using the imaging software provided by the
supplier (SCA 20, version 2.1.5 build 16). To determine the contact
angle, the ﬁrst representative frame in which a drop shape was
observed was selected for analysis. The measurements were conducted
in triplo per sample (n = 3).
2.5. Coating Deposition. Spray coating was performed using an
Exactacoat spraying machine (Sono-Tek) equipped with an Accumist
ultrasonically agitated nozzle. Coating was performed at a dispensing
rate of 1 mL/min, a pressure of 40 mbar and a coating speed of 40
mm/s, by moving both in the xy-direction over a programmed area.
The nozzle height was set 30 mm from the top of the substrate. The
coating density was adjusted by spraying multiple layers of polymer
(coating cycles (n)) onto the substrate. Polymer solutions were
prepared in 2-butanone/2-propanol (v/v, 1:1) with a ﬁnal polymer
concentration of 90 mg/mL. After coating, the patches were dried in a
vacuum oven (50 mbar, 50 °C). The coating density (mg/cm2) was
determined by weighing the patches (before (carrier) and after coating
(carrier + polymer) (mg)) divided by the coated area (cm2).
2.6. Scanning Electron Microscopy. Samples were attached to
an aluminum holder by conducting carbon tape. Afterward, these
samples were sputter coated using a gold/palladium coater
(Cressington 208 HR) for 30 s (80 mA). At diﬀerent magniﬁcations,
images were acquired at an accelerated voltage of 3 kV using a JEOL
6330 Cryo Field Emission Scanning Electron Microscope (SEM).
2.7. Blood Uptake. This experiment was performed using a
procedure adapted from literature.13 Coated gelatin patches with
diﬀerent coating densities (0, 3, 6, and 9 mg/cm2) were weighed (“dry
weight” (mg)) and soaked into a mixture of heparinized blood/PBS
(v/v, 1:1) with the coated side facing the blood mixture. The patches
were allowed to absorb blood for 30 s. After this, superﬁcial blood was
removed using a ﬁlter paper and the patches were weighed again
(“weight after” (mg)) and the amount of absorbed blood (“blood”
(mg)) was determined (wt after (mg) − wt before (mg)). The blood
uptake was deﬁned by calculating the amount of absorbed blood per g
patch. The measurements were performed in 6-fold for each sample (n
= 6). Signiﬁcant diﬀerences between samples were analyzed using
ANOVA followed by a post hoc Tukey-Kramer multi comparison test.
2.8. Adhesion Test. This experiment was performed and designed
according to modiﬁed ASTM F2258−05 standards.39 The samples
were attached with double sided tape to 3D-printed grip tabs of 2 cm2
and these tabs were placed into a single column tensile tester
(Z2,5,Zwick/Roell, Ulm, Germany, containing a 20 N load cell).
Heparinized blood (200 μL) was put between the coated patches
which were pressed down using a weight of 20 g. The patches were
allowed to cross-link with blood for deﬁned times (1, 5, and 15 min).
Subsequently, the patches were pulled apart and the load at failure
(Fmax, N) was measured. The measurements were performed in 6-fold
for each sample (n = 6). Signiﬁcant diﬀerences between samples were
analyzed using ANOVA followed by a post-hoc Tukey-Kramer
multicomparison test.
2.9. In Vivo Eﬃcacy Test. Heparinized (10k units) pigs (n = 4, 30
kg) were used in this study. Permission for this experiment was
granted by the responsible ethical committees at the Ministry of
Education of the Czech Republic (Project #56−2015/processing
#MSMT-42725/2015−6) Surgery was performed using standard
aseptic techniques. A midline laparotomy was performed to access
liver and spleen. Using a biopsy punch, standardized lesions were
created in liver and spleen (8 mm diameter, 3 mm deep). Hemostatic
patches of 2.7 × 2.7 cm were used in this study (n = 8 per prototype
randomized per organ using a balanced latin square). After the lesion
was created, the blood ﬂow was assessed according to a visual scoring
system (0 = no bleeding, 0.5 = oozing, 1 = very slight, 2 = slight, 3 =
moderate, 4 = severe) described in literature.40 Afterward, superﬁcial
blood was removed using a dry gauze. Subsequently, the patches were
applied with the coated side facing the organ and digital pressure was
applied for 1 min using a dry gauze. The eﬃcacy of the patches was
evaluated after 0, 1, and 5 min by monitoring the bleeding (yes or no).
Successful hemostasis was achieved if no bleeding was observed after 5
min without pressure (yes or no). Additionally, after 5 min, the
bleeding was scored according to the scoring system and the adhesion
of the patch to the organ was tested.
2.10. Statistics. Statistical analyses were conducted using Graph-
Pad Instat software. All results were reported as mean ± standard
deviation. Diﬀerences among groups were analyzed by ANOVA using
a Tukey-Kramer Multi comparison test and p-values of 0.05 or lower
were considered as signiﬁcantly diﬀerent.
3. RESULTS AND DISCUSSION
3.1. Synthesis. In order to create poly(2-oxazolines) with
the desired characteristics for application as reactive coating in a
hemostatic patch, both polarity and reactivity had to be
optimized. We selected NHS-esters as the reactive moieties in
view of their reactivity toward primary amines and their routine
application in related medical devices.7 Since direct incorpo-
ration of NHS-esters as functional group is not compatible with
cationic ring opening polymerization (CROP), we used methyl
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ester functionalized 2-methoxycarbonylethyl-2-oxazoline (Mes-
tOx) as monomer instead. This group can be easily modiﬁed
after the polymerization by direct amidation41 or hydrol-
ysis,42−44 as has been described in literature. Furthermore, it
has been eﬃciently copolymerized before with various
comonomers (including 2-ethyl-2-oxazoline (EtOx)45 and 2-
n-propyl-2-oxazoline (nPropOx)46). For the synthesis of the
various POx-NHS (P1−P7) we used two diﬀerent synthetic
routes, as depicted in Scheme 1. In all cases, polymers were
synthesized by CROP of diﬀerent ratios of EtOx, nPropOx, and
MestOx under inert atmosphere using microwave conditions,47
yielding both nPropOx-MestOx and nPropOx-EtOx-MestOx
copolymers. In the ﬁrst route, the MestOx groups were
hydrolyzed (0.1 M NaOH), resulting in a copolymer containing
carboxylic acid moieties, which were subsequently activated
with N-hydroxysuccinimide yielding P1−P6. In the second
route, MestOx was postmodiﬁed by an amidation reaction with
ethanol amine, yielding copolymers equipped with a hydroxyl
Scheme 1. Synthesis of NHS-Ester Functionalized Polymers (POx-NHS; P1−P7)a
aReagents and conditions: (i) methyl tosylate, 140 °C, CH3CN, (ii) 0.1 M NaOH, rt, (iii) NHS−OH, DIC, DCM, rt, (iv) 2-amino-ethanol, 60 °C,
300 mbar, (v) succinic anhydride, DMAP, DMF/DCM (v/v, 1:9, rt).
Table 1. Analytical Data of Synthesized Polymers (P1−P7)
% funct. (1H NMR)
m n x UV Mn (kg/mol)
# polymer m/n/x nPropOx EtOx OH NHS NHS SECa Đa
P1 P(nPropOx-c-NHS) 90−0−10 90 10 11 12.6 1.15
P2 P(nPropOx-c-NHS) 75−0−25 71 29 26 13.9 1.11
P3 P(nPropOx-c-EtOx-NHS) 40−50−10 40 49 11 9 12.4 1.18
P4 P(nPropOx-c-EtOx-NHS) 40−35−25 40 36 24 22 12.4 1.26
P5 P(nPropOx-c-EtOx-NHS) 50−40−10 49 40 11 11 12.3 1.16
P6 P(nPropOx-c-EtOx-NHS) 50−25−25 50 26 24 23 14.6 1.18
P7 P(nPropOx-c-OH-NHS) 70−10−20 70 15 15 15 18.8 1.25
aSEC was calibrated against PMMA standards; eluent: 0.1% LiCl in DMA.
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moiety in the side chain. Subsequently, these hydroxyl groups
were partially converted to carboxylic acid moieties using
succinic anhydride, which were subsequently modiﬁed into
reactive esters by coupling with N-hydroxysuccinimide (P7).
Importantly, this second route installs a hydrolytically sensitive
group in the side chain, favorable for degradation. As listed in
Table 1, polymers P1−P7 were synthesized with good control
over the ratio of functional groups, number-average molar mass
and dispersity values. The various synthesized polymers (P1−
P7) were analyzed with regard to the amount of NHS groups
present using both 1H NMR and UV−vis spectroscopy,
conﬁrming a good agreement between the theoretical and
experimental compositions.
3.2. Hemostatic Performance. As a ﬁrst screening for
hemostatic activity, the POx-NHS polymers were brought in
contact with human whole blood and the formation of gels by
mixing polymers with blood was analyzed using the inverted
vial test. Besides the POx-NHS series, negative controls
(polymers without NHS ester) were tested as well. In addition,
a benchmark polymer (PEG-4-arm NHS used in Hemopatch)
was included as a positive control to compare functional group
density (mmol NHS/g polymer) in relation to the usage of
diﬀerent polymers. The results of these tests are listed in Table
2. As expected, polymers with NHS-esters (P1−P7) gelled with
blood due to the presence of the amine-reactive NHS-esters
groups, unlike the negative controls (P8−P12), which did not.
Gelation times of the POx-NHS series (P1−P7) varied
between 1 min (P7) to 6 min (P1−P2), which was slower
than the PEG-4-arm NHS benchmark polymer, which formed a
gel with blood instantaneously.
As polarity was anticipated to be an important feature of the
hemostatic capacity of the polymers, POx ﬁlms were spin-
coated on glass slides after which static contact angle
measurements were performed.48 Based on these contact
angle measurements, it can be concluded that polymers
functionalized with hydrophilic groups (PEG, OH or EtOX)
(P3−P8 + P10 and P11) exhibit contact angles in a similar
hydrophilic range (21−26°), while polymers without hydro-
philic groups (P1 and P2 + P9) have higher contact angles,
thereby making a clear diﬀerence between hydrophilic and
somewhat more hydrophobic copolymers. It was further
calculated that the PEG-based control (P11) shows a much
lower content of NHS-functional groups (0.36 mmol/g
polymer) compared to P1−P7, with values ranging from 0.76
mmol/g polymer for P1 to 2.19 mmol/g polymer for P2, which
is a direct result of the limited functionalization possibilities of
PEG via the end groups.
From both tests, it can be concluded that NHS-esters are
essential for the formation of chemical cross-links with blood
proteins. However, having a surplus of NHS-esters does not
result in faster gelation. POx-prototypes which contain both
NHS-esters and hydrophilic groups show faster gelation (P3−
P7) compared to polymers without hydrophilic groups (P1 and
P2), but slower than PEG-4arm-NHS (P11), which cross-
linked instantaneously. It was observed that the fast-gelating
polymers also exhibited low contact angles. The diﬀerence in
gelation speed between PEG-4-arm NHS and POx-NHS
prototypes could, however, not be explained from the contact
angle measurements. We assume that polarity and mobility of
the polymer chains (limited by the spacer length between the
polymer backbone and NHS-ester groups) are important
parameters. PEG-4-arm NHS shows the fastest gelation, since
the NHS-ester groups are highly mobile because of their
attachment to the hydrophilic chain ends of the PEG-polymer.
Within the POx-NHS samples, P7 shows the fastest gelation (1
min) because it has a longer spacer between the NHS group
and the polymer backbone compared to P1−P6. Finally, the
diﬀerences between P1−P6, with the same spacer length, can
be explained because of polarity of the polymers; polymers
containing hydrophilic EtOx groups (P3−P6) show gelation
within 3 min, while polymers without these groups (P1 and
P2) show gelation around 6 min. Due to its fast gelation, we
selected P(nPropOx-OH-NHS) (P7) as the main candidate for
further development of hemostatic patches.
3.3. Spray Coating Deposition. To cover the gelatin
carrier with a polymer (P7) coating, a procedure was required
that would result in a homogeneous polymer layer without
compromising the beneﬁcial properties of the gelatin carrier in
terms of, for example, blood uptake capacity. Therefore, we
used an ultrasonic spraying technique to deposit the polymer
from volatile organic solvents of low toxicity onto the gelatin
sponge and tune the amount of polymer by coating multiple
layers (coating cycles) followed by drying the coated patches in
a vacuum oven.
Using this approach, hemostatic patches (G1−G4) were
prepared at various coating densities (0−9 mg/cm2) using a
polymer solution of P7 (90 mg/mL in 2-propanol/2-butanone
(v/v, 1:1)). We observed a linear relationship between the
coating density (mg/cm2) and the amount of coating cycles
(Table 3). Additionally, the coated patches were analyzed by
Table 2. Overview of Hemostatic Performance (P1−P7)
# polymer %NHS functional group contenta (mmol NHS/g polymer) contact angleb (deg) gelation timec (min)
P1 P(nPropOx-c-NHS) 10 0.76 36 6
P2 P(nPropOx-c-NHS) 29 2.19 57 6
P3 P(nPropOx-c-EtOx-NHS) 11 0.89 26 3
P4 P(nPropOx-c-EtOx-NHS) 24 1.59 24 3
P5 P(nPropOx-c-EtOx-NHS) 11 0.88 23 3
P6 P(nPropOx-c-EtOx-NHS) 24 1.57 21 3
P7 P(nPropOx-c-OH-NHS) 15 0.91 23 1
Controls
P8 P(EtOx) 26 no gel
P9 P(nPropOx) 57 no gel
P10 mPEG-OH 24 no gel
P11 PEG-4-arm-NHSd 0.36 21 instantaneous
aCalculated using NHS-content, which was determined by 1H NMR spectroscopy. bThe measurements were conducted in triplo, blank
measurement glass slide (66°). cThe gelation was determined by the inverted vial method. dObtained from commercial source.
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scanning electron microscopy (SEM; Figure 2), which revealed
that the pores of the carrier were not sealed by the polymer
coating after applying up to six coating cycles. Furthermore, the
coating was homogeneously spread onto the carrier material,
unlike Hemopatch (based on 4-arm-PEG), which showed a
heterogeneous coverage revealing PEG-coated and uncoated
domains. The analytical data of G1−G4 are summarized in
Table 3. Importantly, as POx is functionalized with a higher
number of NHS-esters than PEG, a lower amount of polymer
was required (5.7 mg/cm2 for G3) in order to obtain a similar
functional group density as Hemopatch (∼5.2 μmol NHS/
cm2), which is beneﬁcial if an open, porous structure is required
for the carrier material.
3.4. In Vitro Tests. 3.4.1. Blood Uptake. The blood uptake
of the diﬀerent POx-NHS coated patches (G1−G4) and
Hemopatch was evaluated by soaking the patches (with the
coated side in contact with blood) in a mixture of blood/PBS
for 30 s and determining the blood uptake by weighing the
carriers before and after the soaking process (Figure 3A). It was
observed that the uptake capacity of the patches was reduced
Table 3. Coating and Functional Group Densities of Patches
Prepared with P7 (G1−G4)
coating density (mg/cm2)
samples theoretical measured
# mean st dev n
functional group
densitya
(μmol NHS/cm2)
G1 0
G2 3 3.06a 0.01 3 2.80
G3 6 5.71a 0.13 9 5.18
G4 9 9.22a 0.01 3 8.36
Hemopatch
(PEG)
16.8b 2.2 5 5.38
aMass diﬀerence before (gelatin) and after coating (gelatin + POx-
NHS). bDetermined by extraction of the polymer with DCM.
Figure 2. SEM images of POx-NHS coated patches (G1−G4) and Hemopatch (PEG). Scale bars correspond to 1 mm or 100 μm (bottom right
picture).
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with increasing coating density. Although the polymer coating
did not seal oﬀ the pores of the underlying gelatin carrier
(Figure 2), the blood uptake was clearly compromised by the
deposition of POx-NHS onto the patches. Hemopatch was
included as well in these measurements, and showed
signiﬁcantly lower blood uptake values compared to G1−G3.
Since blood uptake is necessary for satisfactory blood
distribution throughout the patch and subsequent cross-linking,
we concluded that G3 was the best-performing prototype in
this test, as it allowed for more eﬀective blood uptake compared
to G4 and Hemopatch, but still prevented bleeding through the
patches, which was observed for G1 and G2.
3.4.2. Adhesion Test. An in vitro adhesion test was
performed (according to ASTM F2258−05 standards) to
study the attachment between the coated patches upon contact
with blood (Figure 3B). The diﬀerent patches (G1−G4) were
allowed to covalently cross-link onto each other for 1, 5, or 15
min, after which the adhesion force (N) was measured until the
patches were separated. Both a negative control (G1, carrier
without polymer) and a benchmark (Hemopatch) were
included in this study. The data demonstrated that the NHS-
ester free blank samples (G1) did not adhere to each other, as
reﬂected by adhesion forces of less than 0.5 N, which conﬁrms
that NHS-ester groups are necessary for the formation of
covalent cross-links. The coated samples (G2−G4) showed an
entirely diﬀerent behavior. At 1 and 5 min contacting time, low
adhesion forces were measured that were comparable to G1,
indicating a low degree of cross-linking. At 15 min, however, a
3-fold larger force (1.5 N) was needed to separate both patches.
This indicates that more cross-links are formed during the
extended cross-linking time (15 min), resulting in larger
adhesion forces. However, since these forces were in the same
range for all three patches, it can be concluded that coating
density did not aﬀect the extent of adhesion in this experiment.
By testing Hemopatch, adhesion forces within 1 and 5 min
were similar to G2−G4 after 15 min. We conclude that this
product generally cross-links fast and forms strong gels with
blood and carrier, which is in agreement with the blood
gelation tests. While the diﬀerences regarding adhesion forces
between the POx-NHS samples (G2−G4) and Hemopatch (15
min) were statistically signiﬁcant compared to NHS-ester free
G1 (15 min), adhesion forces after 15 min were not statistically
diﬀerent between Hemopatch and the POx-NHS samples
(G2−G4). In summary, it can be concluded that Hemopatch
cross-linked faster than POx-NHS samples, whereas the ﬁnal
adhesion strength after 15 min was comparable for both
samples.
3.5. In Vivo Eﬃcacy Test. The POx functionalized patches
were also evaluated in a clinically relevant setting by using an
established in vivo pig model for profuse bleedings.40 In brief,
standardized bleedings (8 mm diameter, 3 mm deep) were
created in the liver and spleen of heparinized pigs (n = 4, 30 kg,
10 k heparin). The bleedings were imaged at selected time
points (0, 1, and 5 min after creation of the bleeding) (Figure
4A) and the hemostatic eﬃcacy of the diﬀerent patches was
assessed at 0, 1, and 5 min (bleeding/no bleeding). In addition,
the bleeding score after 5 min was assessed using a visual
scoring system ranging from 0 (eﬀective hemostasis) to 4
(severe bleeding) (Figure 4B). The eﬃcacy of hemostasis of
POx-NHS coatings was tested for G3, which had a similar
functional group density as the benchmark Hemopatch (∼5.2
mmol NHS/cm2; Table 3), but with a diﬀerent polymer coating
coverage. G1 was used as negative control (no coating). In
addition, Tachosil (a collagen carrier coated with human
derived ﬁbrinogen and thrombin) was selected because of its
common use during liver resections.15 The results of this study
are depicted in Figure 4A,B. G3 was the best-performing
hemostatic patch in this pig model; in 7 out of 8 events,
hemostasis was obtained (bleeding score after 5 min: 0, no
bleeding; Figure 4B). In the remaining event (1 out of 8),
insuﬃcient pressure during application resulted in poor
hemostatic action (bleeding score: 2, slight bleeding) (Figure
4B). In all cases, no signiﬁcant blood ﬂow through the patch
was observed using G3, as was expected from the blood uptake
experiments. Evidently, G1 was not eﬀective at all in this
bleeding model and signiﬁcant blood ﬂow through the patch
was observed in line with the in vitro blood uptake experiments
(Figure 3A). Moreover, in none of the events hemostasis was
Figure 3. (A, B) In vitro tests. (A) Blood uptake capacity as a function
of coating density (**P < 0.001, *P < 0.01); (B) In vitro adhesion test:
(i) blood was applied between the patches, (ii) the patches were
allowed to cross-link for deﬁned time points (t1, t5, t15 min), (iii) the
samples were placed in a Zwick Roell tensile bench and a vertical force
was applied until failure, (iv) results of the adhesion test (*P < 0.05,
**P < 0.01, ***P < 0.001).
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obtained, which can be related to the absence of chemical cross-
linkers. As a result, using G1, in all events, severe bleedings
were scored after 5 min (bleeding score: 4; Figure 4B). In the
experiments using Tachosil, only in 2 out of 8 events
hemostasis was observed, whereas moderate bleedings were
scored for all other cases (Figure 4B). This poor hemostatic
eﬃcacy might be due to the use of a high heparin dose (10 k
units) in this pig model, which inhibits hemostasis solely based
on the natural coagulation cascade. Using Hemopatch, eﬀective
hemostasis was obtained in 5 out of 8 events (Figure 4A),
where bleeding scores varied from 0 (no bleeding) to 3
(moderate bleedings; Figure 4B). Generally, Hemopatch
adhered well and quickly to the tissue, which made
repositioning challenging, a trend that was observed in the in
vitro gelation tests as well. Unlike G3, slight bleeding at the
edges of the patch was observed in cases where hemostasis was
not obtained (Figure 4), which is possibly related to the
inhomogeneous deposition of the polymer coating compared to
the POx-NHS coated patches (Figure 2). From this in vivo
study, it can be concluded that sealants that rely on chemical
cross-linking with surrounding soft tissues and blood proteins
(G3 and Hemopatch) hold great promise for the treatment of
profuse bleeding models, unlike patches which are solely
dependent on the natural coagulation cascade (noncoated
patch (G1) and Tachosil), which were not eﬀective in
obtaining hemostasis in these models. Comparing G3 and
Hemopatch, POx-NHS samples have the additional beneﬁt that
they are coated more homogeneously than Hemopatch, which
results in a uniform sealing of the wound site. In addition, POx-
NHS samples are easier to handle due to their slower adhesion,
which allows repositioning of the patch if required.
4. CONCLUSIONS
In this work, we have successfully developed a hemostatic
device based on NHS-ester functionalized POx coated on a
gelatin patch. We observed that the polymer should contain
both NHS-esters as well as hydrophilic groups to ensure
optimal hemostatic performance. Furthermore, we found that
coating homogeneity and density are crucial parameters in
order achieve the desired hemostatic action in vitro (measured
by adhesion tests) as well as the desired amount of blood
uptake. In vivo eﬃcacy tests in a compromised pig model using
heparin demonstrated that POx-NHS coated patches displayed
a similar hemostatic eﬃcacy as compared to Hemopatch. POx-
NHS patches were superior to products relying on activation of
Figure 4. In vivo study on pig spleen. (A) Images of the diﬀerent prototypes at selected time points (0, 1, and 5 min), including the success rate of
hemostasis. (B) Bleeding scores after 5 min according to the scoring system40
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the natural coagulation cascade. In contrast to PEG, the
structural versatility of POx allows further ﬁne-tuning of the
hemostatic performance, thereby rendering POx-NHS poly-
mers excellent candidates for further development of
hemostatic patches.
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